New combo aims to keep High-Risk myeloma at bay after transplant

NCT ID NCT05776979

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding isatuximab to the standard drug lenalidomide after a stem cell transplant can better control high-risk multiple myeloma. About 61 adults aged 18 to 72 with newly diagnosed high-risk myeloma will receive the combination as maintenance therapy. The main goal is to see how safe and tolerable the treatment is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab and lenalidomide
What this could lead to: If it works, this could offer a more effective maintenance therapy to keep high-risk multiple myeloma from returning after a stem cell transplant.
What could go wrong: This is an early phase 2 trial with only 61 participants, so results may not apply broadly. The combination may cause side effects like infusion reactions or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.